Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT07276763·Not applicable·OBSERVATIONAL

Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention

DulaglutideOtherNot yet recruiting

Status

Not yet recruiting

Phase

Not applicable

Enrollment

16,509

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

A retrospective observational study to explore the impact of discontinuing GLP-1 receptor agonists for two weeks prior to upper endoscopy on the risk of gastric retention

Full detailed description

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, liraglutide, and dulaglutide, are widely used for the management of type 2 diabetes and obesity. These agents improve glycemic control in part by delaying gastric emptying, but this pharmacologic effect may increase the risk of retained gastric contents (RGC) and aspiration during anesthesia or sedation. In 2023, the American Society of Anesthesiologists (ASA) and the American Society for Gastrointestinal Endoscopy (ASGE) issued recommendations to withhold GLP-1RAs before procedures; however, the optimal discontinuation interval remains uncertain. Using the electronic medical record system of Huadong Hospital, this retrospective study analyzed patients who underwent upper endoscopy between August 2023 and May 2025 to examine the association between different GLP-1RA exposure patterns and the risk of RGC, providing evidence to inform optimization of pre-procedural discontinuation strategies.

Interventions

Treatment arms and agents.

OTHER

No Intervention: Observational Cohort

No Intervention: Observational Cohort

Timeline

From registration to results.

  1. First posted

    Dec 11, 2025

  2. Study start

    Dec 10, 2025

  3. Primary completion

    Dec 15, 2025

  4. Study completion

    Dec 15, 2025

  5. Results posted

    Not reported

  6. Registry updated

    Dec 11, 2025

Outcomes

What the study measures.

Primary outcomes

Proportion of gastric retention

Time frame · Immediately at study initiation

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
Not reported
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Undergoing elective upper endoscopy * Complete clinical information available, including endoscopy report, age, sex, BMI, history of diabetes, prior gastric surgery, and gastrointestinal symptom Exclusion Criteria: * Presence of upper gastrointestinal malignancy or obstruction * History of gastric surgery (including ESD, gastrectomy, gastric bypass, etc.) * Emergency endoscopy or non-elective procedures * Missing key clinical information

Study locations

1 registered sites.

China. Showing up to 24 locations stored in the fast local snapshot.

Huadong hospital, Fudan university

Shanghai, Shanghai Municipality, China

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Dulaglutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsDulaglutide trial dashboard →DatabaseDulaglutide database entry →ResearchDulaglutide research guide →